Keywords: lactoferrin; safety; hospital-acquired infection; VLBW infant; AE; Adverse event; bLF; bovine lactoferrin; CoNS; Coagulase-negative staphylococci; FDA; Food and Drug Administration; IND; Investigational New Drug; NEC; Necrotizing enterocolitis; NICU; Neon